Login to Your Account

Lighting a 'Pfizer' top-line, hemophilia B gene therapy due to Spark yeehas at EHA

By Randy Osborne
Staff Writer

Thursday, May 19, 2016

To win proof of concept for gene therapy in the eye previously and now in the liver, with likely read-through from results in hemophilia B with SPK-9001 to efforts in hemophilia A, are "fabulous steps for the company to have taken," noted Spark Therapeutics Inc. CEO Jeffrey Marrazzo.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription